acetylcysteine in Rheumatoid Arthritis
Phase 3
Recruiting
- Conditions
- Rheumatoid arthritis.
- Registration Number
- IRCT20190626044030N1
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 76
Inclusion Criteria
Rheumatoid arthritis patients with a DAS28-ESR score>=2.6
No history of consuming antioxidant supplements within last 2 months
No change of the type and dose of patient's drugs in the last 1 month
No recent infectious disease
Patients that are under treatment with DMARDs
Exclusion Criteria
Biologic agents therapy in the last 6 months
Patients with concurrent autoimmune, rheumatoid disease and gout
Using other complementary and alternative medicine
Pregnancy and lactation
Any addiction to psychotropic agents and opioids
Uncontrolled hypertension
Active gastrointestinal ulcer
History of severe skin allergy
Consuming nitroglycerin
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method IL-1, IL-17, DAS28-ESR, patient global assessment. Timepoint: Base, the end of the fourth week, the end of the eighth week. Method of measurement: Serum level, clinical signs, DAS28-ESR questionnaire.
- Secondary Outcome Measures
Name Time Method ESR, Number of tender joints, number of swollen joints, reduced or increased need for oral or injectable corticosteroids. Timepoint: Baseline, at the end of the fourth week, at the end of the eighth week. Method of measurement: Serum level, clinical examination.